NCT03097848 (ESCALATOR) is a NA clinical trial of RFA in HCC, sponsored by Southwest Hospital, China.

Who is sponsoring NCT03097848?

NCT03097848 is sponsored by Southwest Hospital, China.

What drugs are being tested in NCT03097848?

Interventions in NCT03097848: RFA, Sorafenib.

Is NCT03097848 still recruiting?

NCT03097848 is currently status unknown. Last updated 8 May 2017.

Last reviewed 2017-05-08 · How we verify

NCT03097848: ESCALATOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma

Status unknown NA Last updated 8 May 2017

What this trial tests

NA trial testing RFA in HCC in 450 participants. Status unknown.

Timeline

4 May 2017

Primary endpoint
30 December 2018

31 December 2018

Quick facts

Lead sponsor	Southwest Hospital, China
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	450
Start date	4 May 2017
Primary completion	30 December 2018
Estimated completion	31 December 2018
Sites	1 location across China

Drugs / interventions tested

RFA
Sorafenib (SORAFENIB) — full drug profile →

Conditions studied

HCC — all drugs for HCC →

Sponsor

Southwest Hospital, China

Who can join

Adults 18 to 75, any sex, with HCC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Radiofrequency ablation is a popular treatment for recurrent hepatocellular carcinoma (HCC),but still has a higher recurrence. Sorafenib as neo-adjuvant therapy in combination of RFA was not reported yet. There's a theoretical advantage of this combination. Hence in this study the efficacy and safety of pre-administrative Sorafenib and Latter radiofrequency ablation (RFA) in Recurrent HCC will be tested in a multicenter prospective cohort study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Radiofrequency ablation: mechanisms and clinical applications.
Wu J, Zhou Z, Huang Y, Deng X, et al · · 2024 · cited 24× · PMID 39359691 · DOI 10.1002/mco2.746
Neoadjuvant Therapy for Hepatocellular Carcinoma.
Yin Z, Chen D, Liang S, Li X. · · 2022 · cited 22× · PMID 36068876 · DOI 10.2147/jhc.s357313

Verify or expand the search:

Other trials of RFA

Trials testing the same drug.

NCT07252180 — Comparing Two Different Methods of Ablation of Inlet Patches (APC vs RFA) · NA · active not recruiting
NCT05519319 — Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma · NA · recruiting
NCT05277675 — Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study) · NA · unknown
NCT04530097 — Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC · NA · unknown
NCT04864379 — Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors · Phase 1 · unknown

Other recruiting trials for HCC

Currently open trials in the same condition.

NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
NCT07300488 — Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma · Phase 2, PHASE3 · active not recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07099274 — Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f · Phase 2 · recruiting
NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting

Other Southwest Hospital, China trials

Trials by the same sponsor.

NCT07469293 — Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke · Phase 3 · not yet recruiting
NCT07294209 — Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients · Phase 4 · recruiting
NCT07251374 — Osteomyelitis Multi-center Prospective Cohort Study · not yet recruiting
NCT06894433 — Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage · NA · recruiting
NCT06791538 — Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03097848 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Southwest Hospital, China
Last refreshed: 8 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03097848.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing